TP53 and breast adenocarcinoma: The obtained IC50 values varied from 17.42 μg/ml (against CCRF-CEM leukemia cells) to 38.70 μg/mL (against HCT116 p53−/− colon adenocarcinoma cells) for BAL (Table 2); from 19.11 μM (against CCRF-CEM cells) to 47.50 μM (against MDA-MB-231-BCRP breast adenocarcinoma cells) for compound 1, from 4.07 μM (against MDA-MB-231-pcDNA cells) to 11.44 μM (against HCT116 p53+/+ cells) for compound 2, and from 0.02 μM (against CCRF-CEM cells) to 122.96 μM (against CEM/ADR5000 cells) for doxorubicin.